A Study to Learn About a Vaccine Against E Coli in Healthy Adults
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
| Condition(s) | Healthy Participants |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults. |
| Who can participate | Ages Eligible for Study: 18 to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Key Inclusion Criteria 1. Adult Participants \>= 18 through \< 64 years of age at the time of enrollment. 2. Healthy participants as determined by medical history, physical examination, and clinical judgement of the investigator to be eligible for inclusion in the study. Key Exclusion Criteria 1. Severe adverse reaction history associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 2. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 3. Women who are pregnant, plan to become pregnant during the study, or are breastfeeding. |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Pfizer |
| Locations | Anaheim, California, United States; Lake Forest, California, United States; Walnut Creek, California, United States; Hollywood, Florida, United States; Hollywood, Florida, United States; New York, New York, United States (+5 more sites) |
| Start date | 2025-08-11 |
| NCT ID | NCT07122986 |
| Official listing | https://clinicaltrials.gov/study/NCT07122986 |